Cargando…
The future of alzheimer disease immunotherapies in Saudi Arabia: Consensus statement of the Saudi Chapter of Cognitive and Behavioral Neurology
Alzheimer Disease (AD) constitutes a major global healthcare problem. Standard AD pharmacotherapies offer only modest transient cognitive and behavioral benefits. Aducanumab, an amyloid monoclonal antibody, was the first disease modifying agent to be approved for AD treatment. However, concerns abou...
Autores principales: | Tayeb, Haythum O., Khallaf, Roaa A., Muayqil, Taim A., Alkeridy, Walid A., Alibrahim, Fawwaz S., Alfaify, Omar A., Qadi, Najeeb, Tarazi, Frank I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Riyadh : Armed Forces Hospital
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10155484/ https://www.ncbi.nlm.nih.gov/pubmed/37045461 http://dx.doi.org/10.17712/nsj.2023.2.20220133 |
Ejemplares similares
-
The Common Neurological Presentations and Clinical Outcomes of Coronavirus Disease 2019 in Saudi Arabia
por: Alkeridy, Walid A., et al.
Publicado: (2021) -
The recommended amount of physical activity, sedentary behavior, and sleep duration for healthy Saudis: A joint consensus statement of the Saudi Public Health Authority
por: Alfawaz, Rasha A., et al.
Publicado: (2021) -
Joint consensus statement of the Saudi Public Health Authority on the recommended amount of physical activity, sedentary behavior, and sleep duration for healthy Saudis: Background, methodology, and discussion
por: BaHammam, Ahmed S., et al.
Publicado: (2021) -
Saudi Arabia Guidelines for diabetic macular edema: A consensus of the Saudi Retina Group
por: AlQahtani, Abdullah S., et al.
Publicado: (2021) -
Functional Neurological Disorder in Saudi Arabia: An Update
por: Tayeb, Haythum O
Publicado: (2023)